|
|
|
| Latest News |
| August 26, 2010 |
Volunteers Across the Country Will Hold 50 Fundraising Events in the Next Two Months for Families of SMA to Raise Funds for Research, Support and Hope | Make a difference and join in. Your efforts will help bring us closer to a treatment and make a profound difference in your local community and to the families everywhere affected by SMA. |
|
|
|
| August 24, 2010 |
Project Cure SMA Clinical Network Publishes New Results in Muscle and Nerve | CMAP Assessed as a Potential Clinical Trial Endpoint During CARNI-VAL Trial. Please click here to read more about this study and how CMAP is relevant to SMA. |
|
|
|
| August 20, 2010 |
Spinal Muscular Atrophy Satellite Symposium at Society of Neuroscience | SMA groups to hold symposium at the Society for Neuroscience Meeting entitled "Nucleic Acids to the Rescue: Gene and Antisense Oligonucleotide Therapies for SMA". |
|
|
|
| August 20, 2010 |
Families of Spinal Muscular Atrophy Announces Details on Conference Scholarships for Newly Diagnosed SMA Families. | Families of Spinal Muscular Atrophy is proud to again offer an amazing support program for all newly diagnosed SMA families to attend The Annual SMA Conference in Orlando, Florida on June 23rd – June 26th, 2011. |
|
|
|
| August 19, 2010 |
CARNI-VAL Clinical Trial Results for Spinal Muscular Atrophy Published from Project Cure SMA Network. | Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy. The paper was published today in the online Journal PLoS ONE. This clinical trial was fully funded by Families of SMA. |
|
|
|
| August 19, 2010 |
New Merchandise from Families of SMA for Spinal Muscular Atrophy Awareness Month. | Click here to order. |
|
|
|
| August 11, 2010 |
Rosalind Franklin University Researcher Dr. Michelle Hastings Receives NIH Grant to Pursue Work on the Paratek Compounds for Spinal Muscular Atrophy | Dr. Hastings received key pilot funding from Families of SMA to discover that tetracycline-like molecules developed at Paratek can correct SMN2 splicing and enhance production of SMN protein, as well as to begin development of the compounds for potential clinical use in SMA. |
|
|
|
|
|
|
|
|
|
|
